Cancer, TB Drugs Could Be Taiwan’s Niche Biotech Market – BioBusiness Asia Conference
This article was originally published in PharmAsia News
Taiwan's $2 billion incubator and venture fund will target therapies for locally prevalent cancers in hopes of becoming a regional hub for biotech work.
You may also be interested in...
Regulators from Japan and Taiwan met in late December to review prospects for convergence and pointed to manufacturing and new drug approvals as areas that were ripe for harmonization agreements.
Following an agreement by six multinational firms – including GlaxoSmithKline and AbbVie – to cut prices for antiretrovirals, Taiwan’s Centers for Disease Control is looking to import generic drugs for its free HIV drug reimbursement program, which has met with success only to see costs explode.
Taiwan plans to move as quickly to solicit help from private biotech companies to produce a vaccine for the deadly H7N9 avian flu, with other Asian government watching closely to see if cases appear outside of mainland China.